The COVID-19 pandemic served as an unprecedented "proof of concept" for mRNA technology in Europe. BioNTech’s success in Germany catalyzed a massive wave of investment in mRNA-based protein replacement therapies and cancer immunotherapies. European manufacturers are now repurposing these vaccine platforms to target solid tumors and rare metabolic conditions, leveraging the existing manufacturing infrastructure to reduce the "time-to-clinic" for new drug candidates.

Analysis of the Europe Nucleic Acid Therapeutics Market shows that mRNA therapeutics are expected to hold a significant share of nearly 49% of the RNA-based segment by 2035. European biopharmaceutical companies are increasingly adopting Artificial Intelligence (AI) to optimize mRNA sequences for better stability and reduced immunogenicity. Furthermore, the collaboration between European CDMOs (Contract Development and Manufacturing Organizations) and biotech startups is ensuring that the region remains self-sufficient in its ability to produce high-purity nucleic acid substrates at a commercial scale, securing the supply chain against future global health disruptions.